+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Genmab AS - logo

Genmab is a leading biotechnology company that focuses on developing innovative antibody products. Arzerra is the company’s first marketed antibody and is approved to treat chronic lymphocytic leukemia (CLL) patients in all major markets. Another product, Darzalex, has been approved in the United States for the treatment of patients with multiple myeloma. Genmab was founded in Copenhagen, Denmark in 1999 and employs around 200 people.

Biological Therapies for Cancer: Technologies and Global Markets 2021-2026 - Product Thumbnail Image

Biological Therapies for Cancer: Technologies and Global Markets 2021-2026

  • Report
  • September 2021
  • 258 Pages
  • Global
From
Targeted Therapy Market Report 2025 - Product Thumbnail Image

Targeted Therapy Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
Anti-CD20 Antibody - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD20 Antibody - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 532 Pages
  • Global
From
Melanoma - Pipeline Review, H2 2020 - Product Thumbnail Image

Melanoma - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 3809 Pages
  • Global
From
Fallopian Tube Cancer Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Fallopian Tube Cancer Therapeutics - Global Strategic Business Report

  • Report
  • June 2025
  • 139 Pages
  • Global
From
Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 700 Pages
  • Global
From
CD3 Antigen Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

CD3 Antigen Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Immunotoxins Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Thumbnail Image

Immunotoxins Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • October 2024
  • 94 Pages
  • Global
From
Bladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Bladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 734 Pages
  • Global
From
TRAIL Receptor 2 Agonists - Pipeline Insight, 2025 - Product Thumbnail Image

TRAIL Receptor 2 Agonists - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Cervical Cancer Therapeutics Market - Epidemiology & Pipeline Analysis 2022-2027 - Product Thumbnail Image

Cervical Cancer Therapeutics Market - Epidemiology & Pipeline Analysis 2022-2027

  • Report
  • June 2022
  • 191 Pages
  • Global
From
Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 1560 Pages
  • Global
From
Cervical Cancer Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030 - Product Thumbnail Image

Cervical Cancer Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030

  • Drug Pipelines
  • February 2022
  • 150 Pages
  • Global
From
Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Regional Outlook and Forecast, 2023 - 2030 - Product Thumbnail Image

Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Regional Outlook and Forecast, 2023 - 2030

  • Report
  • November 2023
  • 306 Pages
  • Global
From
TRAIL Receptor 1 & Receptor 2 Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

TRAIL Receptor 1 & Receptor 2 Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
T Cell Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

T Cell Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • August 2022
  • 871 Pages
  • Global
From
Alpha Synuclein Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Thumbnail Image

Alpha Synuclein Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • August 2024
  • 101 Pages
  • Global
From
Pancreatic Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Pancreatic Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • July 2022
  • 3237 Pages
  • Global
From
Loading Indicator